Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma.
Younes
Anas
A
M. D. Anderson Cancer Center, University of Texas, Houston, TX 77030-4009, USA. ayounes@mdanderson.org
Hariharan
Kandasamy
K
Allen
Roberta S
RS
Leigh
Bryan R
BR
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004341:Drug Evaluation; D006801:Humans; D008224:Lymphoma, Follicular / Q000473:pathology / Q000628:therapy*; D015337:Multicenter Studies as Topic; D010865:Pilot Projects; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; C437823:galiximab